-
-
-
-
-
-
-
Corcept Therapeutics (CORT) Misses Q1 EPS by 19c ; Offers Guidance
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) Misses Q4 EPS by 5c ; Offers Guidance
-
-
-
-
-
-
-
CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses
-
-
-
-
-
-
-
Increasing unusual put option volume: SLS AMT IEP HLF ARCC CORT HELE FVRR NOW GNRC ADP
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Corcept Therapeutics (CORT)
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) presents data from CATALYST trial of Korlym
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) Tops Q1 EPS by 2c, provides guidance
-
413,391 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

